Importance Patients who are immunocompromised have increased risk for morbidity and
mortality associated with coronavirus disease 2019 (COVID-19) because they less …

Major changes have occurred in therapeutics for coronavirus-19 (COVID-19) infection over
the past 12–18 mo, most notably in early outpatient therapy. In most cases, solid organ …

Treatment outcomes associated with the use of novel COVID-19 therapeutics in solid organ
transplant recipients (SOTR) are not well described in the literature. The objective of this …

Solid organ transplant recipients (SOTRs) are at risk for severe coronavirus disease 2019
(COVID-19) infection because of immunosuppressive medications and comorbidities. 1, 2 …

Background: Severe COVID-19 appears to disproportionately affect people who are
immunocompromised, although Canadian data in this context are limited. We sought to …

Objectives The effectiveness of a 3-day course of remdesivir to prevent severe disease in
patients with COVID-19 who received solid organ transplant (SOT) is unknown. We wanted …

Abstract The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) has significantly impacted all aspects of …

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) arose in December 2019
in China rapidly evolving to the Coronavirus Disease 2019 (COVID-19) pandemic. Since …

Liver transplantation is a highly complex and challenging field of clinical practice. Although it
was originally developed in western countries, it has been further advanced in Asian …

The SARS-CoV-2 infection has been associated with important mortality, particularly in
immunocompromised patients, including solid organ transplant (SOT) recipients. Remdesivir …